Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech Companies Make Merger Deals

by Ann M. Thayer
November 2, 2009 | A version of this story appeared in Volume 87, Issue 44

Ligand Pharmaceuticals will acquire Metabasis Therapeutics by initially paying about $1.8 million to Metabasis stockholders and making future cash payments if it sells or finds partners for any Metabasis drug development programs. Ligand has agreed to spend at least $8 million in new R&D funding on the Metabasis programs within 42 months of closing the deal. In a more traditional merger, BioMarin Pharmaceutical has paid $15 million to acquire Huxley Pharmaceuticals and its amifampridine phosphate drug for treating Lambert Eaton Myasthenic Syndrome, a rare autoimmune disease. BioMarin will make up to $43.5 million in other payments if the drug hits certain milestones.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.